Differential Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Platelet, Endothelial and Vascular Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01735357
Recruitment Status : Completed
First Posted : November 28, 2012
Last Update Posted : November 28, 2012
Information provided by (Responsible Party):
Dr Wendy Hall, King's College London

Brief Summary:
The purpose of this study was to determine whether supplementation with oils enriched with long chain n-3 PUFA, either EPA or DHA, had a differential effect on platelet, endothelial and vascular function.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: EPA-rich triacylglycerol oil Dietary Supplement: Placebo - olive oil (BP specification) Dietary Supplement: DHA-rich triacylglycerol oil Not Applicable

Detailed Description:

Relatively few studies have made a head-to-head comparison of DHA (22:6n-3) with EPA (20:5n-3). The understanding of this differential effect may be of great interest in populations with low EPA intake such as vegetarians, who may choose to supplement their dietary intake of long-chain n-3 PUFA in the form of DHA-rich algal oil.

This study aimed to investigate the effect of supplementation with oils rich in either EPA or DHA (3g/day, 6 weeks) in healthy young males on platelet, endothelial and vascular function, as well as other CVD risk factors. The primary outcomes were platelet monocyte aggregates and endothelial progenitor cells - novel markers of platelet and endothelial function, measured by flow cytometry, Secondary outcomes included capillary density, measured by capillaroscopy to assess changes in microvascular function, pulse wave analysis, digital volume pulse and ambulatory blood pressure. Other secondary outcomes included lipid profiles (TAG, cholesterol, NEFA), glycaemic control (HOMA, QUICKI) and oxidative stress (isoprostane). The omega-3 index (erythrocyte EPA+DHA) was used as a marker of compliance.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Investigation Into Incorporation of (n-3) Polyunsaturated Fatty Acids Into Erythrocyte Membranes and Clearance, and Effects on Platelet Function, Arterial Function and Endothelial Repair
Study Start Date : June 2009
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Arm Intervention/treatment
Placebo Comparator: Olive oil (BP specification)
5g per day
Dietary Supplement: Placebo - olive oil (BP specification)
Experimental: DHA-rich oil
Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
Dietary Supplement: DHA-rich triacylglycerol oil
Experimental: EPA-rich oil
Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
Dietary Supplement: EPA-rich triacylglycerol oil

Primary Outcome Measures :
  1. Platelet Monocyte Aggregates (PMA) [ Time Frame: 6 weeks ]
    The endothelium plays a vital role in the regulation of blood flow, thrombosis and inflammation. Endothelium-derived anti-adhesive and anti-aggregant substances, including prostacyclin and nitric oxide, are known to inhibit platelet activation. Endothelial dysfunction or vessel wall injury lead to the activation of platelets, of which platelet-monocyte-aggregates (PMA) are a sensitive marker, and were shown to inversely correlate with markers of EF in patients with stable CHD. The measurement of PMA by flow cytometry is a method which reduces ex vivo platelet activation to its minimum and is believed to represent platelet activation in vivo.

  2. Endothelial Progenitor Cell (EPC) counts [ Time Frame: 6 weeks ]
    EPCs are a subgroup of circulating progenitor cells that are recruited from the bone marrow to repair the injured vasculature. They have been associated with a reduced CVD risk and may serve as markers of endothelial function because they represent a greater capacity for the endothelium to repair itself. Two populations of EPCs were measured by flow cytometry, described as 'early EPC' (KDR+/CD34+/CD133+) and 'late EPCs' (KDR+/CD34+/CD31+).

Secondary Outcome Measures :
  1. Capillary density [ Time Frame: 6 weeks ]
    Capillary rarefaction has been associated to CVD risk factors such as hypertension, smoking and obesity. The cutaneous circulation has emerged as an accessible and representative vascular bed to look at microvascular dysfunction. Capillary density was measured by a Capiscope (kk technologies)

  2. Arterial stiffness [ Time Frame: 6 weeks ]
    Pulse wave analysis (PWA) was used to measure indices of arterial stiffness, including peripheral and central augmentation index, as well as central systolic and diastolic blood pressure. Digital volume pulse (DVP) was used to measure reflection and stiffness indices.

  3. Blood Pressure (BP) and Heart Rate (HR) [ Time Frame: 6 weeks ]
    Resting HR and BP were measured in the seated and supine position after 15 minute rest, on the days of both baseline and endpoint visits. In addition, ambulatory BP and HR (24h, daytime, nighttime) was measured 2-3 days prior to each visit.

  4. Plasma isoprostane concentrations [ Time Frame: 6 weeks ]
    8-iso-prostaglandin-F2α (8-IsoP-F2α), a prostaglandin F2-like compound biosynthesized nonenzymatically by a free-radical oxygenation of arachidonic acid, was measured in plasma in order to assess oxidative stress.

  5. Plasma Nitrate and Nitrites (NOx) concentrations [ Time Frame: 6 weeks ]
    Plasma NOx was measured as a circulating marker of endothelial function.

  6. Serum total cholesterol concentration [ Time Frame: 6 weeks ]
  7. Serum Triacylglycerol concentrations [ Time Frame: 6 weeks ]
  8. Serum high density lipoprotein concentration [ Time Frame: 6 weeks ]
  9. Serum low density lipoprotein concentration [ Time Frame: 6 weeks ]
  10. Serum non esterified fatty acids (NEFA) concentration [ Time Frame: 6 weeks ]
  11. Serum Apolipoprotein B concentration [ Time Frame: 6 weeks ]
  12. Plasma glucose concentration [ Time Frame: 6 weeks ]
  13. Plasma insulin concentration [ Time Frame: 6 weeks ]
  14. Serum adiponectin concentration [ Time Frame: 6 weeks ]
  15. Serum resistin concentration [ Time Frame: 6 weeks ]
  16. Erythrocyte phospholipid fatty acid profiles [ Time Frame: 6 weeks ]
    The EPA and DHA content of erythrocyte lipids were used as a marker of compliance.

  17. Fatty acid profile of plasma non esterified fatty acid fraction [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males
  • No smokers
  • Aged 18-45y old
  • Able to understand the information sheet and comply with all the trial procedures
  • Having given written consent to take part in the study prior to participation.

Exclusion Criteria:

  • Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke, dyslipidemia), diabetes (or fasting glucose ≥ 6.1 mmol/L), cancer, kidney, liver or bowel disease.
  • Presence of gastrointestinal disorder or use of drug, which is likely to alter gastrointestinal motility or nutrient absorption.
  • Current smokers; history of substance abuse or alcoholism (previous weekly alcohol intake >60 units/week); current self-reported weekly alcohol intake exceeding 28 units
  • Recent use of hypolipidaemic, antihypertensive, antiplatelet or antithrombotic mediations
  • Platelet count above or below the normal range or any history indicative of a congenital or acquired platelet or haemostatic defect.
  • Allergy or intolerance to any component of study capsules
  • Unwilling to restrict consumption of any source of fish oil for the length of the study
  • Subjects reporting consumption of >1 portion oily fish per week
  • Weight change of >3 kg in preceding 2 months; BMI <18 and >32 kg/m2
  • Blood pressure>160/90 mmHg
  • Fasting blood cholesterol > 6.5 mmol/L; fasting triacylglycerol concentrations > 2.0 mmol/L

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01735357

United Kingdom
Diabetes & Nutritional Sciences Division, King's College London
London, United Kingdom, SE1 9NH
Sponsors and Collaborators
King's College London
Principal Investigator: Wendy L Hall, PhD King's College London

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr Wendy Hall, Lecturer in Nutritional Sciences, King's College London Identifier: NCT01735357     History of Changes
Other Study ID Numbers: EDT
First Posted: November 28, 2012    Key Record Dates
Last Update Posted: November 28, 2012
Last Verified: November 2012

Keywords provided by Dr Wendy Hall, King's College London:
Eicosapentaenoic acid
Docosahexaenoic acid
Cardiovascular risk
Platelet function
Endothelial function
Vascular function
young males